Home  |  Contact

Cellosaurus P3X63Ag8 (CVCL_3411)

[Text version]

Cell line name P3X63Ag8
Synonyms P3x63Ag8; P3-X63-Ag8; P3/X63-Ag8; P3/X63 Ag8; P3/X63/Ag8; P3-X63Ag8; P3X63 Ag8; P3x63 Ag8; P3 x 63Ag8; P3 X 63 Ag8; X63-Ag8; X63-AG8; x63-Ag8; P3X63; X63; GM03571
Accession CVCL_3411
Resource Identification Initiative To cite this cell line use: P3X63Ag8 (RRID:CVCL_3411)
Comments Group: Hybridoma fusion partner cell line.
Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
Doubling time: 16-26 hours (ECACC).
Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
Misspelling: P3-X67Ag8; In PubMed=1172191 figures and table 1.
Disease Mouse plasma cell myeloma (NCIt: C125417)
Species of origin Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Breed/subspecies: BALB/c.
Hierarchy Parent: CVCL_T278 (P3K)
Children:
CVCL_B0T4 (1083-17-1A)CVCL_A6LE (11/9)CVCL_B0T5 (1116-56-2)
CVCL_G218 (1116NS-19-9)CVCL_7233 (1116NS-3d)CVCL_J039 (129A3/1)
CVCL_J042 (130-3-F7-5)CVCL_J040 (130C3/2B/8)CVCL_J041 (132C4A/4)
CVCL_J043 (143-2-A6-11)CVCL_J081 (151-5-G2-12)CVCL_J082 (151-5-G3-5)
CVCL_J083 (151-6-A7-9)CVCL_J084 (15F3-1)CVCL_A0AE (168A51-2)
CVCL_A0AF (168A51-42)CVCL_A0AA (168B17-46-34)CVCL_A0AB (168B17-46-50)
CVCL_A0AC (168B17-46-70)CVCL_A0AD (168B17-46-92)CVCL_WS75 (18B8)
CVCL_J099 (1A3 [Mouse hybridoma against HeLa])CVCL_B0VL (1C1 [Mouse hybridoma against FeLV gp70])CVCL_B0WJ (1C11 [Mouse hybridoma against FIV p24])
CVCL_B0VM (1C12)CVCL_J164 (1G12)CVCL_J165 (1H10-6)
CVCL_J511 (200-3-G6-4)CVCL_CW45 (227-341-4)CVCL_J628 (2C5-6)
CVCL_J720 (3-83P)CVCL_B0WK (3B7 [Mouse hybridoma against FIV p24])CVCL_KB11 (3C5 [Mouse hybridoma against A.australis AaH2])
CVCL_D292 (3H5-1)CVCL_B0VN (4B1)CVCL_KB12 (4C1 [Mouse hybridoma against A.australis neurotoxin AaH2])
CVCL_J813 (4D12)CVCL_G092 (4F2C13)CVCL_J887 (4SB3)
CVCL_J928 (5D4-11)CVCL_B0VP (6B2 [Mouse hybridoma against FeLV p15E])CVCL_B0VQ (6D4)
CVCL_B0VR (6G3)CVCL_B0VS (7B3)CVCL_J052 (7R2/A4)
CVCL_KS90 (8-18C5)CVCL_B0VT (8F3)CVCL_KB13 (9C2)
CVCL_B0WP (A1.1)CVCL_XK76 (A17.2#1)CVCL_J974 (A1G3)
CVCL_XK77 (A25.1#1B3)CVCL_7946 (A2B5 clone 105)CVCL_A7QK (A3D8)
CVCL_L673 (Antibody 2.06)CVCL_XH98 (AS 2)CVCL_XH99 (AS 3)
CVCL_J158 (Aw3.18.14)CVCL_J977 (B1 NIH)CVCL_B0WQ (B1.1)
CVCL_A2DD (B1.12)CVCL_XK78 (B16.1#1B2)CVCL_XK79 (B16.1#1B6)
CVCL_XK80 (B16.1#1C1)CVCL_XK81 (B16.1#1C5)CVCL_XK82 (B16.1#2A2)
CVCL_XK83 (B16.1#2A3)CVCL_XK84 (B16.1#2A5)CVCL_XK85 (B16.1#2C4)
CVCL_XK86 (B16.1#2D2)CVCL_XK87 (B16.1#2D5)CVCL_L832 (B1D6)
CVCL_B0WR (B2.1)CVCL_A2DE (B2.10)CVCL_A2DF (B2.12)
CVCL_J978 (B3 NIH)CVCL_B0WS (B3.1)CVCL_J979 (B5 NIH)
CVCL_4506 (BBM.1)CVCL_J449 (C11C1)CVCL_KR90 (C17.9C6)
CVCL_J890 (D1-4G2-4-15)CVCL_J891 (D3-2H2-9-21)CVCL_G367 (D8G)
CVCL_A1LH (DU-ALL-1)CVCL_A6WW (ECCD-1)CVCL_A6WX (ECCD-2)
CVCL_J226 (F1-3G8-1)CVCL_J237 (F11G)CVCL_H150 (GM03566)
CVCL_H151 (GM03568)CVCL_H149 (GM03705)CVCL_JE56 (GM03713)
CVCL_H152 (GM04279)CVCL_H153 (GM04280)CVCL_5J83 (H14-A11)
CVCL_KR61 (H14-A2)CVCL_5J84 (H14-A20)CVCL_5J85 (H14-A21)
CVCL_5J86 (H14-B18)CVCL_5K02 (H18-S210)CVCL_5K06 (H2-4B3)
CVCL_5K07 (H2-4C2)CVCL_5K08 (H2-6A1)CVCL_L842 (H6/31HL)
CVCL_5J96 (H9-A15)CVCL_5J97 (H9-D3)CVCL_E979 (HFN 36.3)
CVCL_E980 (HFN 7.1)CVCL_3441 (HK-PEG-1)CVCL_2502 (HO-13-4)
CVCL_2503 (HO-2.2)CVCL_2504 (HO-22-1)CVCL_VU59 (Hybrid 15B)
CVCL_VU60 (Hybrid 26A7)CVCL_VU61 (Hybrid 27-1)CVCL_A2IG (I101C9-R1A5)
CVCL_A2IH (I101D4-R1D8)CVCL_A2IK (I101F5-R1G2)CVCL_A2II (I101F8-R1G5)
CVCL_A2IJ (I101H12-R1GB)CVCL_DC76 (IgE-14-205)CVCL_G127 (IL-A11)
CVCL_L579 (IL-A12)CVCL_G198 (J5 [Mouse hybridoma])CVCL_J814 (LS-136)
CVCL_L582 (Mab 126)CVCL_L583 (mAb 13-1)CVCL_L584 (mAb 13-2)
CVCL_L588 (mAb 24-1)CVCL_L589 (mAb 24-2)CVCL_A6QY (MAO A-3C9)
CVCL_A6QZ (MAO A-4F10)CVCL_A6RA (MAO A-7B10)CVCL_A6RB (MAO A-7E10)
CVCL_A6QX (MAO B-1C2)CVCL_A6GC (MAR 103.6)CVCL_D294 (MAR 18.5)
CVCL_A6FM (MAR 80.2)CVCL_A8Q8 (MSN-1)CVCL_L534 (MT3/B4)
CVCL_L535 (MT4/E4)CVCL_UZ12 (P3-Ag8-gamma1-)CVCL_2155 (P3/NS1/1-Ag4.1)
CVCL_4032 (P3X63Ag8.653)CVCL_3412 (P3X63Ag8U.1)CVCL_LI05 (PI 125/10)
CVCL_G250 (PI 153/3)CVCL_LG30 (Rx 54-3)CVCL_A6PE (Sp1/7-2)
CVCL_2199 (Sp2/0-Ag14)CVCL_A6PD (Sp2/3-3)CVCL_D677 (SXC1)
CVCL_J096 (SXC2)CVCL_F770 (T3-3A1)CVCL_G093 (T3-5E9)
CVCL_F784 (TE4 [Mouse hybridoma])CVCL_A2IA (V81C6-R1B6)CVCL_A2IB (V82A6-R1C4)
CVCL_A2IF (V82B1-R2D4)CVCL_A2IC (V82B2-R1F6)CVCL_A2IE (V82G12-R1G1)
CVCL_A2ID (V82G3-R1D6)CVCL_B0D1 (VIIIC3.78)CVCL_7872 (W6/32)
CVCL_F817 (XMMME-001)CVCL_F818 (XMMME-002)CVCL_2Z37 (Y8-10C2)
Sex of cell Female
Category Cancer cell line
Publications

PubMed=1172191; DOI=10.1038/256495a0
Kohler G.J.F., Milstein C.
Continuous cultures of fused cells secreting antibody of predefined specificity.
Nature 256:495-497(1975)

PubMed=825377; DOI=10.1002/eji.1830060713
Kohler G.J.F., Milstein C.
Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion.
Eur. J. Immunol. 6:511-519(1976)

PubMed=6769123; DOI=10.1073/pnas.77.4.2197
Kohler G.J.F.
Immunoglobulin chain loss in hybridoma lines.
Proc. Natl. Acad. Sci. U.S.A. 77:2197-2199(1980)

PubMed=2108149; DOI=10.1016/S0021-9258(19)39438-4
Lee S.-O., Connolly J.M., Ramirez-Soto D., Poretz R.D.
The polypeptide of immunoglobulin G influences its galactosylation in vivo.
J. Biol. Chem. 265:5833-5839(1990)

CLPUB00447
Mulivor R.A., Suchy S.F.
1992/1993 catalog of cell lines. NIGMS human genetic mutant cell repository. 16th edition. October 1992.
(In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992)

Cross-references
Cell line collections ATCC; TIB-9
BCRC; 60340
Coriell; GM03571
ECACC; 85011401
ICLC; ATL05001
JCRB; JCRB9105
NCI-DTP; P3X63
Cell line databases/resources CLDB; cl3840
CLDB; cl3841
CLDB; cl7165
CCRID; 3101MOUTCM9
Lonza; 186
Ontologies BTO; BTO:0001118
CLO; CLO_0008334
CLO; CLO_0017237
Other Wikidata; Q54937286
Entry history
Entry creation04-Apr-2012
Last entry update23-Sep-2021
Version number27